Researchers suggest broadly reactive antibodies identified are likely to represent a common mechanism of acquired immunity to ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Stock recommendation on SIGA Technologies affected by mpox outbreak response, diversifying into mAbs for orthopoxviruses, remains speculative buy.

Monoclonal antibodies (mAbs) have been a key therapeutic option for non-communicable diseases for decades, and a small number of mAbs have helped treat infectious diseases, including COVID-19.

Monoclonal antibodies (mAbs) are manufactured proteins that behave similarly to antibodies found naturally in the body. Researchers initially developed them for treating certain cancers but have ...

Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates Foundation for ...

Japanese drugmaker Chugai, which is majority owned by Roche, On Friday revealed that Zenyaku Kogyo has obtained regulatory ...

Casirivimab and imdevimab in combination is safe among pediatric outpatients with at least 1 risk factor for severe COVID-19.

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Oppenheimer began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note issued to ...

The global protein expression market is expected to reach USD 4.82 billion in 2029 from USD 3.41 billion in 2024 at a CAGR of ...